Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Drug News & Perspectives|January 30, 2004
Hedgehog signaling pathway as a target for therapeutic intervention in basal cell carcinomaJuliet A WilliamsExpert Opinion on Therapeutic Targets|November 23, 2005
Hedgehog and spinal cord injuryJuliet A WilliamsJournal of Clinical Medicine|March 3, 2018
Using PDX for Preclinical Cancer Drug Discovery: The Evolving FieldJuliet A WilliamsProceedings of the National Academy of Sciences of the United States of America|April 8, 2003
Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesionsJuliet A Williams, Oivin M Guicherit, Beatrice I Zaharian, et al.Molecular Cancer Therapeutics|September 19, 2019
Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAF V600-Mutant Melanoma Patient-Derived XenograftsTianshu Feng, Javad Golji, Ailing Li, et al.Elife|April 21, 2017
Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft modelsHui Qin Wang, Ensar Halilovic, Xiaoyan Li, et al.Nature|June 14, 2017
The metabolic function of cyclin D3-CDK6 kinase in cancer cell survivalHaizhen Wang, Brandon N Nicolay, Joel M Chick, et al.Cancer Research|January 28, 2021
Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal MicroenvironmentHui Qin Wang, Iain J Mulford, Fiona Sharp, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase SignalingChen Liu, Hengyu Lu, Hongyun Wang, et al.Frontiers in Immunology|January 30, 2026
Targeted degradation of MK2 is insufficient to block inflammatory cytokine production in human cells due to cooperativity with MK3 and MK5Bin Yang, Guoqiang Fang, Isaac Marx, et al.Pageof 2